A Phase Ib study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors

Jeffrey Goh; Ben Gao; Ben Markman; Hui Gan; Mark Voskoboynik; Yi-Long Wu; Jun Guo; Qing Zhou; Jun Zhao; Cheng Chen; Jingjun Qiu; Yingying Xu; Liu Yang; Michael Millward

doi:10.1158/1538-7445.AM2019-CT167

A Phase Ib study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors

Jeffrey Goh, Ben Gao, Ben Markman, Hui Gan, Mark Voskoboynik, Yi-Long Wu, Jun Guo, Qing Zhou, Jun Zhao, Cheng Chen, Jingjun Qiu, Yingying Xu, Liu Yang, Michael Millward

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Number of pages	2
Journal	Cancer Research
Volume	79
Issue number	13
DOIs	https://doi.org/10.1158/1538-7445.AM2019-CT167
Publication status	Published - Jul 2019
Event	Annual Meeting of the American-Association-for-Cancer-Research (AACR) - Atlanta, United States Duration: 29 Mar 2019 → 3 Apr 2019

Access to Document

10.1158/1538-7445.AM2019-CT167

Cite this

Goh, J., Gao, B., Markman, B., Gan, H., Voskoboynik, M., Wu, Y-L., Guo, J., Zhou, Q., Zhao, J., Chen, C., Qiu, J., Xu, Y., Yang, L., & Millward, M. (2019). A Phase Ib study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors. Cancer Research, 79(13). https://doi.org/10.1158/1538-7445.AM2019-CT167

@article{182e7a6bbf7e474aa1c56dd4a62fc112,

title = "A Phase Ib study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors",

author = "Jeffrey Goh and Ben Gao and Ben Markman and Hui Gan and Mark Voskoboynik and Yi-Long Wu and Jun Guo and Qing Zhou and Jun Zhao and Cheng Chen and Jingjun Qiu and Yingying Xu and Liu Yang and Michael Millward",

year = "2019",

month = jul,

doi = "10.1158/1538-7445.AM2019-CT167",

language = "English",

volume = "79",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research (AACR)",

number = "13",

note = "Annual Meeting of the American-Association-for-Cancer-Research (AACR), AACR ; Conference date: 29-03-2019 Through 03-04-2019",

}

Goh, J, Gao, B, Markman, B, Gan, H, Voskoboynik, M, Wu, Y-L, Guo, J, Zhou, Q, Zhao, J, Chen, C, Qiu, J, Xu, Y, Yang, L & Millward, M 2019, 'A Phase Ib study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors', Cancer Research, vol. 79, no. 13. https://doi.org/10.1158/1538-7445.AM2019-CT167

TY - JOUR

T1 - A Phase Ib study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors

AU - Goh, Jeffrey

AU - Gao, Ben

AU - Markman, Ben

AU - Gan, Hui

AU - Voskoboynik, Mark

AU - Wu, Yi-Long

AU - Guo, Jun

AU - Zhou, Qing

AU - Zhao, Jun

AU - Chen, Cheng

AU - Qiu, Jingjun

AU - Xu, Yingying

AU - Yang, Liu

AU - Millward, Michael

PY - 2019/7

Y1 - 2019/7

U2 - 10.1158/1538-7445.AM2019-CT167

DO - 10.1158/1538-7445.AM2019-CT167

M3 - Abstract/Meeting Abstract

SN - 0008-5472

VL - 79

JO - Cancer Research

JF - Cancer Research

IS - 13

T2 - Annual Meeting of the American-Association-for-Cancer-Research (AACR)

Y2 - 29 March 2019 through 3 April 2019

ER -